• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief


Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Pokaż więcej ( Stron)

Pełen tekst



The Voice of the Editor-in-Chief

Dear Colleagues,

The key challenge in the treatment of diabetes remains the optimization of pharmacological therapy, which has been recently referred as ”individually tailo- red therapy” but still its primary goal is to reduce the risk of development and progression of the disease.

However, besides the search for new ideal diabetes drugs, the equally important problem is the effective and safe use of available diagnostic and therapeutic tools, minimization of adverse drug reactions, increa- sing knowledge about the disease and its acceptability, adherence to recommendations and, consequently, improvement of quality of life of patients with diabetes.

Considering the above, I would like to draw your attention to two of many interesting articles published in the last issue of Clinical Diabetology: the paper presenting an interesting case of using the “old” drug, pioglitazone, on the one hand and the article discussing new possibilities of insulin therapy with ultralong-acting insulin glargine 300 U/mL (Gla-300) on the other hand.

The case study presents pioglitazone therapy in a pa- tient with type 2 diabetes mellitus with poor glycaemic control and elevated transaminase levels in course of non-alcoholic fatty liver disease (NAFLD). Pioglitazone therapy resulted in significant improvement reflected by better glycaemic control and decreased liver enzy- me activity. It is interesting to point out the possible benefits of using pioglitazone in the treatment of type 2 diabetes, because this drug, introduced in the United

States in 1999 and in Europe a year later, is still very rarely used, mainly due to adverse effects of thiazolidinedione class (which it belongs to) and relatively short time since it has been launched into the Polish pharmaceutical market. On the other hand, an article in the pharma- ceutical industry news section, describes insulin glargine 300 U/mL, next (after insulin degludec) ultralong-acting insulin analogue. This article shows new opportunities for basal insulin therapy to achieve lower blood glucose fluctuations and to reduce the risk of hypoglycaemia.

Less fluctuation in blood glucose level, as shown by numerous studies, have been implicated in the reduction of vascular damage, which reduces the risk of vascular complications of diabetes and consequently decreases the costs of treatment and improves the quality of life.

As with insulin degludec, the added benefit is reducing the incidence of hypoglycaemia, including episodes of nighttime or severe hypoglycaemia that are particularly dangerous because patients are often unaware of them and cannot take appropriate corrective measures, which is associated with direct threat to life, but also in the long term leads to brain damage, cognitive function decline and accelerated development of dementia, especially in patients with type 2 diabetes.

I invite you to read and at the same time to actively contribute to our journals, Clinical Diabetology and Diabetologia Praktyczna, by submitting interesting papers and comments on topics discussed.


Prof. Janusz Gumprecht



Powiązane dokumenty

Przekazywał nam też hoj- nie swoje wiadomości, choć byliśmy w wieku, kiedy na ogół nie docenia się wielu skarbów pchających się w ręce.. Na szczęście zapamiętałam zdradzone

„Rodzina w systemie wsparcia społecznego i pomocy osobom z problemem alkoholowym”, zorganizowana przez Pracownię Pedagogiki Specjalnej, w ramach realizowanego

The foregoing ruminations suggest that today’s urbanism needs the doctrine of harmonious urban development which can be formulated like this: activities bringing changes in the space

Celem artykułu jest przedstawienie wyników badań własnych na temat poziomu wiedzy finansowej mieszkańców terenów peryferyjnych województwa podkarpac- kiego.. Wybór

Professor Janusz Gumprecht has excellently developed the journal — it appears regularly, contains more and more papers from outside Poland, is included in the Web of Science

Just before the publication of this issue of “Cli- nical Diabetology”, the largest diabetes meeting in the world — 79 th Scientific Sessions of the American Diabetes

Although more than 3,500 years have passed since the first description of the symptoms of diabetes in the Egyptian papyrus dated to around 1550 BC, diabetes is still

differences in the frequency, causes and duration of hospitalization of children with diabetes in different regions of Poland, which implies the need to ensure uniform access

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would

In accordance with other diabetic organizations (the American Diabetes Association — ADA, the National Institute for Health and Care Excellence — NICE), glycaemic goals has

Here, it should be mentioned that also the LEADER trial, that assessed cardiovascular safety of one of GLP-1 agonists, liraglutide, in the population of type 2 diabetes

Despite recent advances in medicine, introduction of new hypoglycaemic drugs and the fact that more than 3.500 years have passed since the earliest known record of diabetes

The conference brought together a group of distinguished lecturers and almost 500 participants — physicians dealing in their everyday practice with carbohydrate

At the same time, we intend to continue the educational function of the journal and we do not want to hinder the access to its content for the readers; therefore, we decided

This change is a result of systematic de- velopment of our journal aiming at further increasing its presence and importance on the international arena and striving to